曼恩凯德生物医疗 2025年季度报告

Form 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025Or☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934For the transition period fromto.Commission file number: 000-50865 MannKind Corporation (Exact name of registrant as specified in its charter) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that theregistrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required tobe submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months(or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company, or an emerging growth company. See the definitions of “large acceleratedfiler,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of theExchange Act. Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any new or revised financial accounting standards provided pursuant toSection 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of April 25, 2025, there were 303,932,852 shares of the registrant’s common stock, $0.01 par value per share,outstanding. MANNKIND CORPORATION Form 10-Q For the Quarterly Period Ended March 31, 2025TABLE OF CONTENTS PART I: FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited)2Condensed Consolidated Statements of Operations: Three months ended March 31, 2025 and 20242Condensed Consolidated Statements of Comprehensive Income: Three months ended March 31, 2025 and20243Condensed Consolidated Balance Sheets: March 31, 2025 and December 31, 20244Condensed Consolidated Statements of Stockholders’ Deficit: Three months ended March 31, 2025 and 20245Condensed Consolidated Statements of Cash Flows: Three months ended March 31, 2025 and 20246Notes to Condensed Consolidated Financial Statements7Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations33Item 3. Quantitative and Qualitative Disclosures About Market Risk39Item 4. Controls and Procedures39 PART II: OTHER INFORMATION Item 1. Legal Proceedings40Item 1A. Risk Factors40Item 2. Unregistered Sales of Equity Securities and Use of Proceeds70Item 3. Defaults Upon Senior Securities70Item 4. Mine Safety Disclosures70 PART 1: FINANCIAL INFORMATIONITEM 1. FINANCIAL STATEMENTSMANNKIND CORPORATION AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited) See notes to condensed consolidated financial statements. MANNKIND CORPORATION AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(Unaudited) Three MonthsEnded March 31,20252024(In thousands)Net income$13,158$10,630Other comprehensive income:Unrealized loss on available-for-sale securities65—Comprehensive income$13,223$10,630 See notes to condensed consolidated financial statements. MANNKIND CORPORATION AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited) Other intangible assets5,2175,265Other assets28,05526,757Total assets$410,141$393,843 MANNKIND CORPORATION AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT(Unaudited) MANNKIND CORPORATION AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) MANNKIND CORPORATION AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1. Description of Business and Significant Accounting Policies The unaudited condensed consolidated financial statements of MannKind Corporation and its subsidiaries(“MannKind,” the “Company,” “we” or “us”), have been prepared in accordance with generally acceptedaccounting principles in the United States of America (“GAAP”) for interim financial information and with theinstructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (the“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for completefinancial statements. The information included in this quarterly report on Form 10-Q should be read inconjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal y